158 related articles for article (PubMed ID: 23676600)
1. Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Nishijima Y; Hirata H; Himeno A; Kida H; Matsumoto M; Takahashi R; Otani Y; Inoue K; Nagatomo I; Takeda Y; Kijima T; Tachibana I; Fujimura Y; Kumanogoh A
Intern Med; 2013; 52(10):1111-4. PubMed ID: 23676600
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of drug therapy of lung cancer in Hungary].
Moldvay J; Rokszin G; Abonyi-Tóth Z; Katona L; Kovács G
Magy Onkol; 2013 Mar; 57(1):33-8. PubMed ID: 23573520
[TBL] [Abstract][Full Text] [Related]
3. Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Ho C; Ramsden K; Zhai Y; Murray N; Sun S; Melosky B; Laskin J
J Thorac Oncol; 2014 Aug; 9(8):1180-6. PubMed ID: 25157771
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Spigel DR; Hainsworth JD; Shipley DL; Ervin TJ; Kohler PC; Lubiner ET; Peyton JD; Waterhouse DM; Burris HA; Greco FA
J Thorac Oncol; 2012 Jan; 7(1):196-202. PubMed ID: 21900836
[TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Ramalingam S; Belani C
Oncologist; 2008; 13 Suppl 1():5-13. PubMed ID: 18263769
[TBL] [Abstract][Full Text] [Related]
6. [Second-line treatment for advanced non-small-cell lung cancers].
Akita H
Gan To Kagaku Ryoho; 2005 Jan; 32(1):15-8. PubMed ID: 15675575
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
9. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
Bischoff HG; Heigener DF; Walzer S; Nuijten M
Lung Cancer; 2010 Aug; 69 Suppl 1():S18-23. PubMed ID: 20727458
[TBL] [Abstract][Full Text] [Related]
10. MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):13. PubMed ID: 24852397
[No Abstract] [Full Text] [Related]
11. Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
Zhang YM; Li YQ; Liu ZH; Liao XL; Liang R; Lin Y; Yuan CL; Liao SN; Liang CY; Li Q; Li LQ
Asian Pac J Cancer Prev; 2014; 15(8):3447-50. PubMed ID: 24870737
[TBL] [Abstract][Full Text] [Related]
12. [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Yokoba M; Yanase N; Masuda N
Gan To Kagaku Ryoho; 2005 Jun; 32(6):783-8. PubMed ID: 15984516
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.
Nuijten M; Heigener DF; Bischoff HG; Chouaid C; Vergnenègre A; de Castro Carpeño J; Aultman R; Walzer S; Siebert U
Lung Cancer; 2010 Aug; 69 Suppl 1():S4-10. PubMed ID: 20727460
[TBL] [Abstract][Full Text] [Related]
14. [Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Yano S
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):699-704. PubMed ID: 24796139
[No Abstract] [Full Text] [Related]
15. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab-induced laryngeal necrosis.
Hartl DM; Bahleda R; Hollebecque A; Bosq J; Massard C; Soria JC
Ann Oncol; 2012 Jan; 23(1):276-278. PubMed ID: 22056850
[No Abstract] [Full Text] [Related]
17. [Perforation of the nasal septum: a rare complication of bevacizumab].
Bylicki O; Boursier C; Peloni JM; Dot JM
Rev Mal Respir; 2012 Nov; 29(9):1124-6. PubMed ID: 23200586
[TBL] [Abstract][Full Text] [Related]
18. [A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Tambo Y; Kasahara K; Fujimura M; Tamori S; Araya T; Sone T; Nakao S
Gan To Kagaku Ryoho; 2007 Feb; 34(2):217-9. PubMed ID: 17301530
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
Giuliani G; Grossi F; de Marinis F; Walzer S
Lung Cancer; 2010 Aug; 69 Suppl 1():S11-7. PubMed ID: 20727457
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Hanna N
J Thorac Oncol; 2006 Nov; 1(9):927-8. PubMed ID: 17409973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
